Adenosine Vials Rx
Generic Name and Formulations:
Adenosine 3mg/mL; soln for IV infusion; preservative-free.
Various generic manufacturers
Indications for Adenosine Vials:
Adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to undergo adequate exercise stress.
Give peripherally as a continuous IV infusion. ≥18yrs: 140mcg/kg/min over 6 mins for a total dose of 0.84mg/kg. Infusion rate (mL/min)= 0.140 (mg/kg/min) x total body weight (kg)/adenosine conc. (3mg/mL). See full labeling.
<18yrs: not established.
2nd- or 3rd-degree AV block or sinus node disease (eg, sick sinus syndrome, symptomatic bradycardia), unless paced. Bronchoconstructive or bronchospastic disease (eg, asthma).
Have resuscitative measures available. Increased risk of cardiovascular events in patients with acute MI, unstable angina, or cardiovascular instability; avoid use. Pre-existing 1st-degree AV block or bundle branch block. Discontinue if persistent or symptomatic high-grade AV block or hypotension occurs. Autonomic dysfunction. Stenotic valvular heart disease. Pericarditis or pericardial effusions. Stenotic carotid artery disease with cerebrovascular insufficiency. Hypovolemia. Obstructive lung disease (eg, emphysema, bronchitis). Discontinue if severe respiratory difficulties occur. Elderly. Pregnancy (Cat.C). Nursing mothers.
May be potentiated by β-blockers, cardiac glycosides, calcium channel blockers; use caution. Increased risk of seizures with concomitant methylxanthines (eg, caffeine, aminophylline, theophylline): not recommended. Potentiated by dipyridamole.
Flushing, chest discomfort, dyspnea, headache, throat/neck/jaw discomfort, GI discomfort, lightheadedness/dizziness; cardiac arrest, sustained ventricular tachycardia, MI, bronchoconstriction, hypo- or hypertension, cerebrovascular accident, convulsive seizures, atrial fibrillation.
Formerly known under the brand name Adenoscan.
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Pharmacologically Induced Headache Accompanied by Dilated Cephalic Vessels
- IV Lidocaine May Be Safe, Efficacious for Pediatric Status Migraine
- Gray Matter Changes in Migraine Associated With Clinical Characteristics